3 results
Primary Objective: To determine whether topical application of Calcitriol (Silkis) 3 µg/g, Diclofenac 10% or a combination of both can lead to a 40% histological reduction (*)/increase (*) of expression of the following antibodies: Ki67 (*), BCL2…
In this pilot study, we are setting on to investigate the differential effects of the VDR activator paricalcitol versus calcitriol on peritoneal transport, peritoneal inflammation and peritoneal defense parameters in PD patients.
The primary objectives of this investigation are to evaluate whether pre-acquired Amycard ECGI map-guided LV lead placement (I) improves CRT volumetric response compared to non-guided (empiric) LV lead placement, and (II) reduces the distance to LV…